Collectively, these results indicated the specific overexpression of the transcription factor ATF5 in malignant T cells among CTCL patients, which were associated with inferior therapeutic outcomes. Here, ATF5 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.